TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.


Options:
A: Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group
B: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
C: Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.


Options:
A: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
B: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo granules | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo granules; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
C: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): montelukast
D: Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mannitol | Arm Label: Montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): Montelukast

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Arm Label: Placebo Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide | Intervention Type: DRUG; Name: Placebo Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide
B: Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A
C: Arm Label: Beclomethasone dipropionate; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate | Arm Label: Beclomethasone dipropionate/Salbutamol combination; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate/Salbutamol combination | Arm Label: Salbutamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salbutamol | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Beclomethasone dipropionate | Intervention Type: DRUG; Name: Beclomethasone dipropionate/Salbutamol combination; Assigned to Arm(s): Beclomethasone dipropionate/Salbutamol combination | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Salbutamol
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Budesonide/formoterol; Assigned to Arm(s): N/A
C: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
B: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
D: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Memantine for AIDS Dementia Complex (ADC) as Concurrent Treatment With Antiretroviral Therapy
Brief Summary: The purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving AIDS dementia complex (ADC).

The symptoms of ADC can be improved with zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, and the effectiveness of ZDV seems to decrease during the second and third years of therapy. The effectiveness of other antiretroviral drugs as treatment for ADC is not known, so it is important to explore alternative therapies.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART)
Brief Summary: This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART). The purpose of this study is to see if IL-2 can increase the number of CD4 cells (cells of the immune system which fight infection) in HIV-infected patients who have completed ACTG 328.

HAART is often successful in decreasing viral load (level of HIV in the blood), but these drugs have not been able to restore the immune systems of HIV-infected patients. IL-2 is a substance naturally produced by the body's immune cells. In ACTG 328, IL-2 is tested to see if it can increase the number of CD4 cells and "boost" a patient's immune system. This study is a follow-up to ACTG 328 so that patients who are benefiting from IL-2 can continue to take it and patients in the control group who do not receive IL-2 can start taking it.


Options:
A: Arm Label: Antiretroviral therapy alone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proleukin plus antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Drug: Proleukin | Intervention Type: DRUG; Name: Proleukin; Assigned to Arm(s): Proleukin plus antiretroviral therapy
B: Arm Label: No IL-2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IL-2 without ART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Arm Label: IL-2 with pericycle HAART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Intervention Type: DRUG; Name: IL-2; Assigned to Arm(s): IL-2 with pericycle HAART, IL-2 without ART
C: Arm Label: rIL-2; Type: EXPERIMENTAL; Interventions: Drug: Recombinant interleukin-2 (rIL-2) | Arm Label: No rIL-2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant interleukin-2 (rIL-2); Assigned to Arm(s): rIL-2
D: Intervention Type: DRUG; Name: Indinavir sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bipolar Genetics: A Collaborative Study
Brief Summary: This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions....


Options:
A: Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)
B: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
C: Arm Label: Less Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: More Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Less Dependent Smokers, More Dependent Smokers
D: Arm Label: Healthy Volunteers; Type: N/A; Interventions: N/A | Arm Label: Patients; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endocrine Studies of Healthy Children
Brief Summary: Researchers would like to determine normal ranges for hormone levels and to learn more about the genetics involved in hormone production and action. Researchers will take samples of blood, urine, saliva, and stool from healthy children ages 5-17 in order to study different aspects of hormones.

Establishing a range of normal hormone levels in children will make diagnosing illnesses with abnormal levels of hormones much easier. Hormone levels in the body can change throughout the day. By collecting samples at different times researchers hope to learn more about the normal daytime and nighttime patterns of hormone secretion. Because some hormone levels change with body size, researchers will also take measurements of patient's body composition.

This study will involve children and observe them as inpatients or as outpatients. \<TAB\>


Options:
A: Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol
B: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide
C: N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Orlistat; Type: EXPERIMENTAL; Interventions: Drug: Orlistat | Intervention Type: DRUG; Name: Orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C